|Número de publicación||US7776029 B2|
|Tipo de publicación||Concesión|
|Número de solicitud||US 10/057,144|
|Fecha de publicación||17 Ago 2010|
|Fecha de presentación||24 Ene 2002|
|Fecha de prioridad||30 Ene 2001|
|También publicado como||US20040082908|
|Número de publicación||057144, 10057144, US 7776029 B2, US 7776029B2, US-B2-7776029, US7776029 B2, US7776029B2|
|Inventores||Todd K Whitehurst, Kelly H McClure, James P McGivern|
|Cesionario original||The Alfred E. Mann Foundation For Scientific Research|
|Exportar cita||BiBTeX, EndNote, RefMan|
|Citas de patentes (38), Otras citas (3), Citada por (10), Clasificaciones (17), Eventos legales (8)|
|Enlaces externos: USPTO, Cesión de USPTO, Espacenet|
The present application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/265,419, filed Jan. 20, 2001, which application is incorporated herein by reference in its entirety.
The present invention generally relates to implantable medical devices, and more particularly to an implantable microminiature infusion pump; and/or a system comprising a plurality of implantable microdevices and external devices used to provide therapeutic substances, including electrical stimulation, to a patient.
Pharmaceutical developments have yielded dozens of new drugs each year for the past decade. As the identification and understanding of the various hormones, cytokines, neurotransmitters, and various other chemical regulators and messengers has increased, the ability to harness these substances therapeutically also increases. Additionally, with the advent of gene therapy, a new method of treating disease is beginning to be developed.
The significant advances in the therapeutic substances delivered to patients have been accompanied by a somewhat slower development of methods and means of drug delivery. Some of the newer substances are simply not amenable to the paradigm of taking a pill once or a few times a day. For instance, a number of newly developed substances, such as peptides and strands of DNA, are deactivated or destroyed by the gastrointestinal system, immune system, liver, and/or lymphatic system before they reach the systemic circulation in any significant or reproducible level. Other substances must be maintained at a minimum level in order to achieve a therapeutic effect, e.g., heparin. Other substances have a narrow therapeutic window, i.e., the minimum required dose is not far below the maximum recommended dose. Additional examples exist, including substances that may need to be targeted to a site to avoid systemic side effects.
Several methods of convenient parenteral drug administration are now commercially available. Depot formulations of medications have been available for some years, e.g., Depo-Provera, a form of contraception that lasts to 3 months. Transdermal patches are available for the delivery of substances such as fentanyl, nicotine and testosterone. A long-lasting, slow-dissolving formulation of contraceptive is now available from Norplant, and provides a means of contraception that offers protection from pregnancy for up to 5 years.
More invasive systems have become available recently as well. External infusion pumps have been available for a number of years, e.g., the Medtronic MiniMed external insulin pump, made by Medtronic MiniMed Inc. of Northridge, Calif. Implantable infusion pumps are also available for systemic delivery of substances, e.g., the Medtronic MiniMed implantable insulin pump. External and internal infusion pumps are now also used for the delivery of substances to a targeted area, e.g., intrathecal delivery of opiates and cancer site delivery of chemotherapy agents. The infusion rate of some such systems may be adjusted transcutaneously.
The DURECT DUROS osmotic infusion pump, commercially available from Durect, of Cupertino, Calif., is typically implanted via a minimally invasive procedure and provides delivery of medication for up to several months. However, the infusion rate is not adjustable following implantation.
The following U.S. patents describe various types of infusion pumps known in the art: U.S. Pat. Nos. 3,731,681; 4,457,752; 4,557,673; 4,911,616; 5,041,107; 5,045,064; 5,049,141; 5,514,103; 5,637,095; 5,678,296; 5,697,951; 5,733,259; 5,785,681; 5,697,951; 5,733,259; 5,785,681; 5,820,589; 5,888,530; 5,957,890; 6,120,665; 5,667,491; 6,022,316; 6,014,584; 5,869,326; and 6,110,161.
A review of the above-referenced prior art indicates that there is still a need for a minimally-invasive implantable infusion pump that, once implanted, can be controlled in meaningful ways to customize it to suit the needs of a particular patient. Moreover, a review of the prior art indicates that there is also a need a minimally-invasive infusion pump that may be combined with other forms of treatment and therapy, e.g., electrical stimulation therapy.
The present invention provides means of subacute or chronic drug delivery via a microminiature infusion pump that can be implanted with a minimal surgical procedure. In some embodiments, the infusion rate may be programmed so that it may vary over time, or in response to an external stimulus, e.g., a command from a remote control. The micro-pump also, in some embodiments, incorporates means of electrical stimulation, thereby providing a complementary or additional therapy. For example, the pump combined with electrical stimulation may be used in the case of electrical nerve stimulation combined with analgesic infusion for pain control.
The above and other aspects of the present invention will be more apparent from the following more particular description thereof, presented in conjunction with the following drawings wherein:
The following description is of the best mode presently contemplated for carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of describing the general principles of the invention. The scope of the invention should be determined with reference to the claims.
In the description that follows, reference should be made generally to the figures,
The present invention is directed to a system including means for delivering at least one therapeutic substance to a patient, the therapeutic substance delivery means comprising a microminiature implantable infusion pump, such as the pump 10 shown in
As seen best in
The device also includes a driver 30 for driving a fluid(s) out an exit portal(s) 12A, 12B in the device. The driver 30 may be adjusted by circuitry 38 internal to the device, e.g., based on a desired time-infusion rate profile, and/or by an external device 50, e.g., a sensor device or a remote control. In some embodiments, the driver 30 is a pump of the diaphragmatic or peristaltic type, or the like, in which the moving part(s) force fluid out of the reservoir by creating areas of increased and/or decreased pressure and/or by applying force to the reservoir 40 or other temporary container of fluid(s). The driver 30, e.g., pump, may be actuated by electrostatic and/or electromagnetic means.
In certain embodiments, the driver 30 used to drive a fluid(s) out an exit portal(s) is a negative pressure pump (typified by U.S. Pat. Nos. 4,482,346 and 4,486,190, incorporated herein by reference). Such negative pressure pump may be a solenoid-activated negative pressure device. A diaphragm separates the drug from propellant, such as Freon maintained at negative pressure, or the like. The solenoid is activated, driving an armature and a bellows pumping element. The displacement of the armature opens a check valve that draws drug from a reservoir(s) into a downstream pumping chamber. A restriction is used to prevent backflow in the outlet during this short period. When the pump chamber is full, the check valve closes and the solenoid is de-energized. A spring force is used to displace the bellows into the chamber thereby pumping the drug through a restrictor and into the patient. The bellows armature assembly comes to rest on the check valve to insure that no backflow occurs during the rest period. Such a system operates at negative pressure to ensure no forward, flow during this rest period, i.e., the drug chamber pressure is less than body pressure.
In various embodiments, the driver 30 for driving a fluid(s) out an exit portal(s) comprises a positive pressure pump used in combination with an accumulator pump (typified by U.S. Pat. Nos. 4,221,219; 4,299,220; and 4,445,224, incorporated herein by reference). Such driver may also incorporate redundant or fail-safe valves together with sensor/shutdown circuits to prevent accidental delivery of the fluid(s) contained in the reservoir.
The microminiature pump 10″ shown in
In several embodiments, the regulator 32 for adjusting infusion rate consists of a number of multi-stable valves. Such multi-stable valves may be of any suitable design apparent to those skilled in the art, e.g., shape-memory valves or micro-machined valves. The number of possible settings of the multi-stable valves determines the maximum possible number of allowable programmable states, i.e., infusion rates. In some embodiments, the regulator 32 alternatively or additionally includes a pressure responsive control valve for connecting a secondary restrictor such as an additional capillary tube in series with the baseline flow path, to prevent undesired increase in the infusion rate in the event that the patient temporarily encounters a high altitude ambient pressure.
The microminiature pump 10′ of the invention also includes at least one an exit portal, allowing the fluid 39 to egress from the device. In some embodiments, an exit portal(s) 12A, 12B is/are substantially flush with the device, i.e., the device contains no catheter. The exit portals 12A and 12B are in fluid communication with the driver 30, e.g., pump, via tubing or channels 34, or the like. In various embodiments such as shown in
The microminiature pump device further includes, in some embodiments, a non-occlusion device 35 for ensuring that an exit portal(s) is not occluded or that it may be cleared if occluded, e.g., by tissue or debris from a patient's body. Such non-occlusion device 35 typically includes a mechanical device, such as a wiper or a plunger, that periodically or episodically clears an occluded lumen. Such non-occlusion device may alternatively or additionally include an electrical pulse(s) or other electrical signal that may disintegrate an occlusion. Such device may alternatively or additionally compress or expand the exit portal(s), such that the occlusion is broken down or is otherwise allowed to escape. Such non-occlusion device may alternatively or additionally include the application of a high fluid pressure behind the occlusion to force it out of the exit portal(s). Alternatively or additionally, the non-occlusion device may include a filter over the exit portal(s). The microminiature pump device may trigger the non-occlusion device upon sensing that an occlusion is present, e.g., through detection of increased pressure in the pump or the restrictor.
The microminiature pump device 10, 10′, 10″, 10′″, 20, or 20′ of the present invention further includes, in certain embodiments, a means of transcutaneous refilling 15. For instance, one or more thin membranes 15 or septum-like material overlying one or more reservoirs 40 may be punctured by a hypodermic needle (e.g., syringe), but typically does not allow any significant leakage of fluid or substance following such puncture. For the embodiment shown in
In embodiments as shown in
The microminiature pump device 10″ additionally includes electrical stimulation means 45 for providing electrical stimulation of tissue, including two or more electrodes 14A and 14B that are on the surface of the device 10″ and/or on leads attached to the device. Such electrical stimulation may take the form of a series or sequence of electrical pulses of a type typically used for, e.g., stimulation of nerve and muscle tissue. Alternatively, such electrical stimulation may take the form of very high-voltage electrical pulses. The electrical stimulation may alternatively comprise an electrical generator that generates a DC or slowly varying waveform. The electrical stimulation means may be configured to operate in conjunction with the fluid infusion means of the microminiature pump device. Alternatively, the electrical stimulation means may operate as an alternative to the fluid infusion means. In the latter case, two microstimulators may be implanted: a microminiature drug delivery infusion pump and an electric stimulation “micro-pump”.
The microminiature infusion pump device of the invention may deliver one or more medications or other substances. A single device may be implanted, or two or more devices may be implanted to achieve drug infusion, pulses of electric current, and/or direct electric current application to a larger region or for a longer period of time, as shown in
The dotted line 47 shown in
The length and the shape of the microminiature infusion pump may be varied in order to deliver more effective treatment. According to embodiments of the invention as shown in
The number and orientation of electrodes 14A, 14B, and/or 14C, 14D, that are present on a device made in accordance with the invention may be varied. According to embodiments of the invention as depicted in
The microdevice of the present invention may be controlled to provide drug infusion and/or electric stimulation either intermittently or continuously. Specific infusion parameters and/or specific electrical parameters provide therapeutic advantages for various diseases. According to some embodiments of the invention, the infused substance(s) are administered systemically, and at the same time the microstimulator is activated to produce electric stimulation for a first period of time. The microstimulator continues to provide electric stimulation for a second predetermined period of time following the administration of the infused substance(s), e.g., two (2) hours. According to certain embodiments of the invention, the microstimulator provides electric stimulation continuously, and the electric stimulation may potentiate the effects of a substance(s) and/or may provide direct effects on tissue.
The power source used as a means for providing power to the implantable microdevice of the present invention may be realized using one or more of the following approaches, or other power source/storage options:
According to some embodiments of the invention, the implanted microdevice may operate independently. According to other embodiments of the invention, the implanted microdevice operates in a coordinated manner with other similar implanted microdevices, other implanted devices, or other devices external to the patient's body, e.g., as shown by the control lines 62, 63 and 64 in
A micro-pump device made in accordance with the invention may incorporate communication means for communicating with one or more external or site-specific drug delivery devices; and further may have the control flexibility to synchronize and control the duration of drug delivery. The associated drug delivery device typically, but not necessarily, provides a feedback signal that lets the control device know it has received and understood the command. The communication signal between the micro-pump device and the drug delivery device may be encoded to prevent the accidental or inadvertent delivery of drugs by other signals.
A micro-pump device made in accordance with the invention further incorporates, in some embodiments, a first sensor 68 for sensing therapeutic effects, clinical variables, or other indicators of the state of the patient. The micro-pump device may additionally or alternatively incorporate a second sensor 69 for sensing levels and or changes in one or more hormones, enzymes, neurotransmitters and/or their associated breakdown products, cytokines, medications and/or other drugs, and/or other substances in the blood plasma or local interstitial fluid, using, e.g., one or more Chemically Sensitive Field-Effect Transistors (CHEMFETs) such as Enzyme-Selective Field-Effect Transistors (ENFETs) or Ion-Sensitive Field-Effect Transistors (ISFETs, as are available from Sentron CMT of Enschede, The Netherlands). The micro-pump device may additionally or alternatively incorporate a third sensor 70 for sensing electrical current levels and waveforms supplied by another source of electrical energy. Sensed information may then be used to control the infusion and/or electrical parameters of the micro-pump device in a closed loop manner, as shown by control lines 66, 67, and 65, and/or by an external device(s), as shown by control lines 62, 63, and 64.
According to some embodiments of the invention, the sensing and infusion are both incorporated into a single micro-pump device. According to other embodiments of the invention, the sensing and electrical stimulation are both incorporated into a single micro-pump device. According to yet other embodiments of the invention, the sensing, drug infusion, and electrical stimulation are all incorporated into a single micro-pump device. According to various embodiments of the invention, the sensor(s) are incorporated into at least one “micro-pump device” (that may or may be capable of infusion), and the sensed information is, if desired, communicated to at least one other micro-pump device capable of infusion. The implant circuitry amplifies and transmits these sensed signals, if necessary, which may be analog or digital. Information sensed by the sensor(s) may then be used to control the electrical, infusion, and/or control parameters in a closed-loop manner.
Additionally, a sensor(s) described earlier may be used to orchestrate first the activation of one microdevice, and then, when appropriate, another microdevice targeting the same or another area of the body, in order to, for instance, control symptoms by a different means. Alternatively, this orchestration may be programmed, and not based on a sensed condition.
While the invention herein disclosed has been described by means of specific embodiments and applications thereof, numerous modifications and variations could be made thereto by those skilled in the art without departing from the scope of the invention set forth in the claims.
|Patente citada||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US3731681||14 Ene 1972||8 May 1973||Univ Minnesota||Implantable indusion pump|
|US4221219||31 Jul 1978||9 Sep 1980||Metal Bellows Corporation||Implantable infusion apparatus and method|
|US4299220||3 May 1979||10 Nov 1981||The Regents Of The University Of Minnesota||Implantable drug infusion regulator|
|US4360019||31 Mar 1980||23 Nov 1982||Andros Incorporated||Implantable infusion device|
|US4457752||13 Sep 1982||3 Jul 1984||Csaba Vadasz||Surgically implantable pump|
|US4482346||30 Jul 1982||13 Nov 1984||Consolidated Controls Corporation||Apparatus for infusing medication into the body|
|US4486190||27 Dic 1982||4 Dic 1984||Consolidated Controls Corporation||Precision medication dispensing system and method|
|US4557673||17 Oct 1984||10 Dic 1985||Novacor Medical Corporation||Implantable pump|
|US4772263||23 Sep 1987||20 Sep 1988||Regents Of The University Of Minnesota||Spring driven infusion pump|
|US4911616||19 Ene 1988||27 Mar 1990||Laumann Jr Carl W||Micro miniature implantable pump|
|US5041107||6 Oct 1989||20 Ago 1991||Cardiac Pacemakers, Inc.||Electrically controllable, non-occluding, body implantable drug delivery system|
|US5045064||1 Jun 1990||3 Sep 1991||Infusaid, Inc.||Constant pressure implantable pump reservoir|
|US5049141||25 Abr 1990||17 Sep 1991||Infusaid, Inc.||Programmable valve pump|
|US5061242||18 Jul 1989||29 Oct 1991||Infusaid, Inc.||Adjustable implantable drug infusion system|
|US5374285 *||30 Jul 1993||20 Dic 1994||Aries S.R.L.||Spinal electrode catheter|
|US5382236||29 Nov 1991||17 Ene 1995||Anschutz & Co., Gmbh||Implantable infusion pump|
|US5514103||14 Jun 1994||7 May 1996||Minimed Inc.||Medication infusion pump with improved pressure reservoir|
|US5578077||19 Ago 1994||26 Nov 1996||Kassatly; Samuel A.||Mechanical heart, body fluid and drug infusion pump|
|US5637095||13 Ene 1995||10 Jun 1997||Minimed Inc.||Medication infusion pump with flexible drive plunger|
|US5697951||25 Abr 1996||16 Dic 1997||Medtronic, Inc.||Implantable stimulation and drug infusion techniques|
|US5704908 *||10 Oct 1996||6 Ene 1998||Genetronics, Inc.||Electroporation and iontophoresis catheter with porous balloon|
|US5722957||15 Mar 1996||3 Mar 1998||Fresenius Ag||Implantable infusion pump|
|US5728396||30 Ene 1997||17 Mar 1998||Alza Corporation||Sustained delivery of leuprolide using an implantable system|
|US5733259||22 Dic 1994||31 Mar 1998||Gensia Pharmaceuticals, Inc.||Method and apparatus for closed loop drug delivery|
|US5785681||25 Feb 1997||28 Jul 1998||Minimed Inc.||Flow rate controller for a medication infusion pump|
|US5814019||15 Mar 1996||29 Sep 1998||Fresenius Ag||Implantable infusion pump|
|US5820589||30 Abr 1996||13 Oct 1998||Medtronic, Inc.||Implantable non-invasive rate-adjustable pump|
|US5836915||18 Sep 1995||17 Nov 1998||Fresenius Ag||Implantable infusion pump|
|US5888530||18 Jul 1996||30 Mar 1999||The General Hospital Corporation||Method of enhancing delivery of a pharmaceutical formulation|
|US5957890||9 Jun 1997||28 Sep 1999||Minimed Inc.||Constant flow medication infusion pump|
|US6048328||2 Feb 1998||11 Abr 2000||Medtronic, Inc.||Implantable drug infusion device having an improved valve|
|US6148222 *||10 Jul 1998||14 Nov 2000||Cardiocommand, Inc.||Esophageal catheters and method of use|
|US6238367||28 Abr 2000||29 May 2001||Medtronic, Inc.||Electrical connector for transducer of implantable drug infusion device|
|US6283951 *||25 Mar 1998||4 Sep 2001||Transvascular, Inc.||Systems and methods for delivering drugs to selected locations within the body|
|US6464687||9 Mar 2000||15 Oct 2002||Ball Semiconductor, Inc.||Implantable drug delivery system|
|US6485464||28 Abr 2000||26 Nov 2002||Medtronic, Inc.||Reduced height implantable drug infusion device|
|US20010053887||1 May 2001||20 Dic 2001||Joel Douglas||Micro infusion drug delivery device|
|US20020087147||4 Ene 2001||4 Jul 2002||Hooper Sandra Marie||Implantable infusion pump|
|1||"DUROS implant technology", printed May 14, 2001, pp. 1-2.|
|2||"DUROS technology: how does it work?", printed May 14, 2001, pp. 1-2.|
|3||"DUROS", printed May 14, 2001, pp. 1-2.|
|Patente citante||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US8105269||24 Oct 2008||31 Ene 2012||Baxter International Inc.||In situ tubing measurements for infusion pumps|
|US8137083||11 Mar 2009||20 Mar 2012||Baxter International Inc.||Infusion pump actuators, system and method for controlling medical fluid flowrate|
|US8382447||31 Dic 2009||26 Feb 2013||Baxter International, Inc.||Shuttle pump with controlled geometry|
|US8496613||30 Ene 2012||30 Jul 2013||Baxter International Inc.||In situ tubing measurements for infusion pumps|
|US8567235||29 Jun 2010||29 Oct 2013||Baxter International Inc.||Tube measurement technique using linear actuator and pressure sensor|
|US9192719 *||1 Nov 2010||24 Nov 2015||Medtronic, Inc.||Implantable medical pump diagnostics|
|US9662436||18 Sep 2014||30 May 2017||Icu Medical, Inc.||Fail-safe drug infusion therapy system|
|US9714650||13 Dic 2013||25 Jul 2017||Matthew G. Morris, Jr.||Pumping system|
|US20120109099 *||1 Nov 2010||3 May 2012||Medtronic, Inc.||Implantable medical pump diagnostics|
|US20160199568 *||9 Ene 2015||14 Jul 2016||BioQuiddity Inc.||Sterile Assembled Liquid Medicament Dosage Control And Delivery Device|
|Clasificación de EE.UU.||604/890.1|
|Clasificación internacional||A61K9/22, A61M5/142, A61N1/34, A61N1/32|
|Clasificación cooperativa||A61N1/32, A61M2005/14208, A61M5/14228, A61M2205/0244, A61M2205/054, A61M5/14224, A61M2205/3523, A61M5/14276, A61N1/36071|
|Clasificación europea||A61N1/36Z3C, A61N1/36Z, A61M5/142P10|
|28 Mar 2002||AS||Assignment|
Owner name: ADVANCED BIONICS CORPORATION, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WHITEHURST, TODD K.;MCCLURE, KELLY H.;MCGIVERN, JAMES P.;REEL/FRAME:012532/0656
Effective date: 20020123
|7 Ene 2008||AS||Assignment|
Owner name: INFUSION SYSTEMS, LLC, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOSTON SCIENTIFIC NEUROMODULATION CORPORATION;REEL/FRAME:020329/0853
Effective date: 20080107
|14 Abr 2008||AS||Assignment|
Owner name: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION, CAL
Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED BIONICS CORPORATION;REEL/FRAME:020796/0264
Effective date: 20071116
|5 Feb 2014||FPAY||Fee payment|
Year of fee payment: 4
|5 Feb 2014||AS||Assignment|
Owner name: ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH,
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INFUSION SYSTEMS, LLC;REEL/FRAME:032147/0343
Effective date: 20091229
|2 May 2014||AS||Assignment|
Owner name: ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH,
Free format text: SECURITY INTEREST;ASSIGNOR:MEDALLION THERAPEUTICS, INC.;REEL/FRAME:032815/0188
Effective date: 20140331
|6 May 2014||AS||Assignment|
Owner name: ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH,
Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SCHEDULE WHICH REFLECTED PATENT NUMBER AS 8,327,041 AND SHOULDHAVE BEEN REFLECTED AS 8,372,041. PREVIOUSLY RECORDED ON REEL 032815 FRAME 0188. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST;ASSIGNOR:MEDALLION THERAPEUTICS, INC.;REEL/FRAME:032827/0478
Effective date: 20140331
|9 May 2014||AS||Assignment|
Owner name: MEDALLION THERAPEUTICS, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH;REEL/FRAME:032892/0067
Effective date: 20140331